Skip to main content
. Author manuscript; available in PMC: 2014 Oct 7.
Published in final edited form as: Cancer. 2008 Dec 1;113(11):3186–3191. doi: 10.1002/cncr.23919

TABLE 3.

Response by Therapy

Therapy No. of Patients No. of CRs (%)
VAD/hyper-CVAD 61 17 (28)
Cytarabine combinations 54 17 (32)
Allogeneic bone marrow transplantation 22 9 (41)
Methotrexate-asparaginase combinations 52 3 (6)
Other combinations 29 4 (14)
Single agent 70 3 (4)

CRs indicates complete responses; VAD, vincristine, doxorubicin, and dexamethasone; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.